Cell Therapy Market Size, Analysis, Trends, Sector / Industry Report & Analysis 2020, & Forecast 2021-2026 (Includes Business Impact of COVID-19)

                                          
Abstract, Snapshot, Market Analysis & Market Definition: Global Cell Therapy Market


The global Cell Therapy market size is projected to reach US$ 8.34 billion by 2026, from US$ 6.1 billion in 2020, at a CAGR of 5.34% during 2021-2026.The market is poised to benefit from the inclusion of new cell types, which in turn, provide substantial opportunities to companies to reinforce their market position. As a result, the number of companies involved in cell therapy development has increased tremendously over the past years.

Rising funding from government as well as private organizations to support cell therapy clinical trials, introduction of effective guidelines for cell therapy manufacturing, and proven effectiveness of products are some of the primary growth stimulants for the market. In addition, declining prices of stem cell therapies are leading to increased inclination of buyers towards cell therapy.

Development of cell banking facilities and resultant expansion of production, storage, and characterization of cells are enhancing volumetric capabilities of the cytotherapy market at a global level. This, in turn, has directly translated into increase in revenue generation for the stem cells and non-stem cells therapy market in the past years.
Furthermore, regulatory bodies are engaged in providing support to innovators for introduction of novel and effective solutions for patients as quickly as possible. Moreover, existing companies are working in collaboration with regulatory agencies in order to best fit into regulatory model for cell therapies.

Despite being slightly ethically as well as legally controversial, the market is gaining significant attention from entities involved in various aspects of disease management. Healthcare practitioners are making significant use of stem cells derived from bone marrow or blood in transplant procedures for treatment of patients with cancer, blood disorders, and immune-related disorders.

Furthermore, the market is largely influenced by commercialization of unauthorized stem cell treatments. As of June 2016, there were around 351 companies across the U.S. that were engaged in advertising unauthorized stem cell treatments at their clinics. Such clinics boosted the revenue in this market.

However, in August 2017, the U.S. FDA announced increased enforcement of regulations and oversight of clinics involved in practicing unapproved stem cell therapies. This might hamper the revenue generation during the forecast period; nevertheless, it will allow safe and effective use of stem cell therapies.

Market Segmentation, Outlook & Viewpoint: Global Cell Therapy Market

Use & Type Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025)

Clinical-use

  
By Therapeutic Area
  
Malignancies
  
Muscoskeletal Disorders
  
Autoimmune Disorders
  
Dermatology
  
Others

By Cell Therapy Type

  
Stem Cell Therapies
  
BM, Blood, & Umbilical Cord-derived Stem Cells
  
Adipose derived cells
  
Others
  
Non-stem Cell Therapies

Research-use

Therapy Type Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025)

  
Allogenic Therapies
  
Autologous Therapies

Key Players, Recent Developments & Regional Insights: Global Cell Therapy Market

There are a limited number of FDA approved stem and non-stem cell therapies in the market for commercial usage. Thus, the stem cells and non-stem cells market for clinical-use accounted for a lesser share in 2017, compared to the research-use segment. Furthermore, wind down of LAVIV (Azficel-T) in 2017, manufactured and offered by Fibrocell Technologies, has reduced the revenue growth to a certain extent in 2017.

Some examples of approved cell therapies for clinical applications are MACI, Epicel, Cellgram-AMI, Cupistem, Cellistem IC CARTISTEM, Invossa, Prochymal, Imlygic, and GINTUIT. The market for clinical-use is further bifurcated into stem cell-based and non-stem cell-based therapies. Non-stem cell therapies comprising therapies developed from collagen-producing fibroblast cells, immune cells, cartilage cells, keratinocytes, and others are poised to witness noteworthy growth during the forecast period.

On the flip side, stem cell therapies derived from blood cells, adipose tissues, and others are projected to witness a decline in their revenue growth. This decline can be attributed to tedious and elaborated process of cell production.

Therapy Insights

Across the globe, development and sales of allogeneic stem cell therapies has been greater than autologous therapies. The high cost associated with the former coupled with presence of a relatively large number of market entities involved in this therapy development has led to a larger share of the segment in the global cell therapy market (stem cells & non-stem cells).

Kolon TissueGene, Inc.; JCR Pharmaceuticals Co., Ltd.; and MEDIPOST are some of the companies that are engaged in catering products in this segment. However, the market exhibits growth potential for both allogeneic and autologous therapies.

Autologous therapies are anticipated to register a significant rate during the forecast period owing to several advantages offered by them such as availability, lower risk of life-threatening complications, low rate of graft failure, low mortality rate, higher affordability, and high survival rate of patients. Some companies that are involved in delivering autologous therapies are Fibrocell Technologies, Vericel Corporation, and Dendreon.

Regional Insights

North America is projected to hold the largest share in the global market throughout the forecast horizon. Strong regulatory framework for promoting cellular therapy development, high cost of therapies in the U.S., and presence of a raft of companies are promoting the growth of the regional market. The U.S. is estimated to be the leading revenue contributor in the region. However, as compared to current U.S. market, Canadian market accounted for a lesser share in the North America cellular therapy market.

The Asia Pacific market is anticipated to experience the highest growth during the same period. Rising investments by developers and consumers in educating themselves for advanced medicinal therapies are expected to stimulate the growth of the market in emerging economies of this region.

Pricing of stem cell transplant varies from region to region. For instance, cost of transplantation in the U.S. is observed to be costlier than that in Germany or China. Furthermore, revenue for certain products varies in different countries owing to different approval policies. For instance, products such as Invossa, Cupistem, and Cellgram-AMI have received approval from Ministry of Food and Drug Safety for distribution of the product in Korea but is yet to receive marketing authorization in the U.S.

Cell Therapy Market (Stem Cells & Non-Stem Cells) Share Insights

Some of the key companies operating in the market are Kolon TissueGene, Inc.; JCR Pharmaceuticals Co. Ltd.; MEDIPOST; Osiris Therapeutics, Inc.; Stemedica Cell Technologies, Inc.; Cells for Cells; NuVasive, Inc.; Fibrocell Science, Inc.; Vericel Corporation; PHARMICELL Co., Ltd.; ANTEROGEN.CO.,LTD. These companies are collaborating with blood centers and plasma collection centers in order to obtain cells for use in therapeutics development.

Furthermore, companies are undertaking efforts for the expansion of customer base, by promoting it to surgeons for usage in transplantation procedures. For example, in February 2017, Vericel Corporation conducted first implant of MACI in the U.S. for treatment of symptomatic multiple or single full-thickness cartilage defects of the knee. Post this, the company began channelizing its strategies to increase the number of surgeons employing its products in transplantation procedures.

Key Insights Covered: Global Cell Therapy Market

1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Cell Therapy industry.
2. Global major manufacturers" operating situation (sales, revenue, growth rate and gross margin) of Cell Therapy industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Cell Therapy industry.
4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Cell Therapy industry.
5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Cell Therapy industry.

Research Methodology: Global Cell Therapy Market

  
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
  
Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
  
Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other